TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07264959: An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

Sponsor: Blueprint Medicines Corporation · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 150 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$498,000

Rescue Site Savings

+$332,000

Unlock Full NCT07264959 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07264959 Rescue Dossier →